Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 15/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NMBR | P28336 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6771514 | 0.98 | SIRT2 (0.44) | SIRT2CYP11B1CYP11B2ENPP2NOTUM | |
| Acetic Acid SCHEMBL7659782 | 0.92 | SIRT2 (0.47) | SIRT2CYP11B1CYP11B2ENPP2NOTUM | |
| SCHEMBL9069663 | 0.87 | SIRT2 (0.44) | SIRT2P2RX7 | |
| SCHEMBL1041048 | 0.87 | SIRT2 (0.49) | SIRT2CYP11B1CYP11B2ENPP2NMBR | |
| SCHEMBL7713289 | 0.84 | SIRT2 (0.46) | SIRT2NMBR | |
| SCHEMBL7939506 | 0.84 | SIRT2 (0.40) | SIRT2CYP11B1CYP11B2ENPP2NMBR | |
| SCHEMBL2032778 | 0.84 | SIRT2 (0.47) | SIRT2CYP11B1CYP11B2ENPP2NMBR | |
| SCHEMBL4682888 | 0.83 | SIRT2 (0.46) | SIRT2CYP11B1CYP11B2ENPP2NMBR | |
| SCHEMBL1924923 | 0.83 | SIRT2 (0.45) | SIRT2CYP11B1CYP11B2ENPP2NOTUM | |
| SCHEMBL2038903 | 0.83 | SIRT2 (0.45) | SIRT2CYP11B1CYP11B2ENPP2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0760811-A1 | IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H 3? (ANT)AGONISTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1997-03-12 | — | — | EP | claimed |
| JP-1294682-A | — | — | None | — | — | JP | disclosed |
| EP-4630424-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | Third Harmonic Bio, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250197368-A1 | 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS | DRAIG THERAPEUTICS LTD. (GB) | 2025-06-19 | — | — | US | disclosed |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2024240240-A1 | IMIDAZOLE DERIVATIVES, INTERMEDIATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏恩华药业股份有限公司 | 2024-11-28 | — | — | WO | disclosed |
| CN-118994283-A | Beta-D-galactopyranose compound, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-11-22 | — | — | CN | disclosed |
| CN-118684633-A | Androgen receptor modulators and methods of use thereof | 埃萨制药股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20240254119-A1 | COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS | Calixis Inc. | 2024-08-01 | — | — | US | disclosed |
| CN-113195441-B | Androgen receptor modulators and methods of use thereof | 埃萨制药股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-5026722-A | Antagonists of 5-hydroxytryptamine | GLAXO GROUP LIMITED (GB) | 1991-06-25 | — | — | US | disclosed |
| EP-0383281-A1 | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1990-08-22 | — | — | EP | disclosed |
| EP-0369743-A2 | Heterocyclic amides | ZENECA LIMITED (GB) | 1990-05-23 | — | — | EP | disclosed |
| JP-H01294682-A | PRODUCTION OF PHOSPHATIDYLCHOLINE | NIPPON OIL & FATS CO LTD | 1989-11-28 | — | — | JP | disclosed |
| US-4882343-A | ADRENERGIC BLOCKING AGENTS | G. D. SEARLE & CO. (US) | 1989-11-21 | — | — | US | disclosed |
| EP-0338939-A1 | Histamine derivative, process for his preparation and his therapeutic application | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1989-10-25 | — | — | EP | disclosed |
| US-4814343-A | ANTIISCHEMIC | U C B, S.A. (BE) | 1989-03-21 | — | — | US | disclosed |
| EP-0306323-A2 | Lactam derivatives | GLAXO GROUP LIMITED (GB) | 1989-03-08 | — | — | EP | disclosed |
| EP-0304910-A1 | Biarylalkylimidazole derivatives as antidepressants | G.D. Searle & Co. (US) | 1989-03-01 | — | — | EP | disclosed |
| EP-0269599-A2 | Substituted 1H-imidazoles | U C B, S.A. (BE) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | SIRT2 1787/4885CYP11B1 143/4885CYP11B2 399/4885 |
| US-20240254119-A1 | COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS | KIT, AURKC, PRKCE | SIRT2 4277/4885CYP11B1 4060/4885CYP11B2 4434/4885 |
| US-20250197368-A1 | 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS | GABRA2, GABRA3, GABRB2 | SIRT2 1384/4885CYP11B1 595/4885CYP11B2 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.